Experienced in Gaucher Disease Type 3

Dr. Michael A. Kosmo

Hematology Oncology
625 Citracado Pkwy, #110, 
Escondido, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Gaucher Disease Type 3
625 Citracado Pkwy, #110, 
Escondido, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Kosmo is a Hematologist Oncology provider in Escondido, California. Dr. Kosmo is rated as an Experienced provider by MediFind in the treatment of Gaucher Disease Type 3. His top areas of expertise are Anemia, Breast Cancer, Paget Disease of the Breast, and Drug-Induced Thrombocytopenia.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

625 Citracado Pkwy, #110, Escondido, CA 92025

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Enrollment Status: Recruiting
Publish Date: November 01, 2023
Intervention Type: Drug
Study Drugs: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone
Study Phase: Phase 1
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Phase 2, Open-Label, Dose-Ranging Study of SPI-2012 (HM10460A) or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen
Enrollment Status: Completed
Publish Date: April 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane
Enrollment Status: Terminated
Publish Date: July 30, 2021
Intervention Type: Drug
Study Drugs: Tesetaxel and Capecitabine, Capecitabine
Study Phase: Phase 3
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials
Similar Doctors
Experienced in Gaucher Disease Type 3
Dr. James M. Sinclair
Hematology Oncology | Hematology | Oncology
Experienced in Gaucher Disease Type 3
Dr. James M. Sinclair
Hematology Oncology | Hematology | Oncology

California Cancer Associates For Research And Excellence Inc

16918 Dove Canyon Rd, 
San Diego, CA 
 (5.4 miles away)
858-649-5100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Sinclair is a Hematologist Oncology specialist and a Hematologist in San Diego, California. Dr. Sinclair is rated as a Distinguished provider by MediFind in the treatment of Gaucher Disease Type 3. His top areas of expertise are Non-Hodgkin Lymphoma, Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma.

Experienced in Gaucher Disease Type 3
Dr. Philip B. Dreisbach
Hematology Oncology | Hematology | Oncology
Experienced in Gaucher Disease Type 3
Dr. Philip B. Dreisbach
Hematology Oncology | Hematology | Oncology

Desert Hematology-Oncology Medical Group Inc

34490 Bob Hope Dr, 
Rancho Mirage, CA 
 (60.0 miles away)
760-568-3613
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Dreisbach is a Hematologist Oncology specialist and a Hematologist in Rancho Mirage, California. Dr. Dreisbach is rated as a Distinguished provider by MediFind in the treatment of Gaucher Disease Type 3. His top areas of expertise are Familial Colorectal Cancer, Paget Disease of the Breast, Breast Cancer, and Pleuropulmonary Blastoma.

Experienced in Gaucher Disease Type 3
Dr. Divya T. Koura
Hematology Oncology | Hematology | Oncology
Experienced in Gaucher Disease Type 3
Dr. Divya T. Koura
Hematology Oncology | Hematology | Oncology

Regents Of The University Of California

200 W Arbor Dr, 
San Diego, CA 
 (23.8 miles away)
858-657-7000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Divya Koura is a Hematologist Oncology specialist and a Hematologist in San Diego, California. Dr. Koura is rated as a Distinguished provider by MediFind in the treatment of Gaucher Disease Type 3. Her top areas of expertise are Graft Versus Host Disease (GvHD), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kosmo's expertise for a condition
ConditionClose
    View All 19 Advanced Conditions
    View All 87 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile